A NEW STANDARD IN OXYGEN THERAPY

Venous Leg Ulcers form a significant portion of the growing silent epidemic of chronic wounds. Using innovative proprietary materials and simple technology that is fully compatible with current standard of care, our goal is to give patients back ulcer-free time in life and break the cycle of clinical burden on clinicians and payers.

A REVOLUTIONARY APPROACH TO OXYGEN THERAPY

Welcome to Substrato Medical. We are a newly founded Medtech Startup based in Ireland whose goal is to bring a game-changing technology into the treatment of chronic wounds, starting with Venous leg Ulcers.

Our innovative device technology is called Docleaf, which through its unique material technology and design brings a breakthrough option of effective tissue oxygenation into current standard of care.

Initiated in 2024 through the renowned Bioinnovate program by our CEO, Liam O’Brien, the technology has been developed with the experts in Regenerative Medicine at RCSI.

SUPPORTERS & AFFILIATIONS

Venous leg ulcers are part of a growing silent epidemic of chronic wounds, creating a major clinical and economic burden on patients and healthcare systems alike.

Affecting an estimated 4% of people over 65 and contributing to approximately 3.2 million patients annually across the US and Europe, these wounds are often slow to heal, difficult to manage, and highly recurrent. The result is a significant and growing strain on healthcare resources, with costs estimated at $15Bn in the U.S. and €6.5Bn in Europe alone.

POOR HEALING OUTCOMES CONTINUE TO DEFINE VENOUS LEG ULCER CARE

24% Non healing | 50% Recurrence

THE PROBLEM WITH VENOUS LEG ULCERS

Often overlooked, chronic wounds are a rising global healthcare challenge with significant human and economic impact.
Venous leg ulcers disproportionately affect older adults and contribute to millions of cases across major healthcare markets each year, with 3.2 million patients each year in the US and Europe.
Long treatment times, recurrence, and intensive care needs drive a substantial and sustained cost burden across the U.S. .the US and EU. Healthcare cost burden was estimated close to $15Bn in the US and €6.5Bn in the EU.